



Exploring the Benefits and Controversies of EDTA Chelation Therapy

Pascal Janet*

Department of Pediatrics, Sullivan University, USA

INTRODUCTION

In the world of alternative medicine, various therapies and treatments have emerged to address health concerns beyond conventional practices. One such therapy that has gained attention is EDTA chelation. EDTA, or ethylenediaminetetraacetic acid, is a synthetic amino acid widely known for its ability to bind to and remove heavy metals from the body.

DESCRIPTION

Chelation therapy involves the administration of chelating agents, such as EDTA, to remove heavy metals and other toxins from the body. The process works by forming stable chemical complexes with metal ions, which are then excreted through urine. Originally developed in the 1930s for industrial purposes, EDTA's ability to bind to heavy metals sparked interest in its potential medical applications. Today, chelation therapy is primarily utilized to treat heavy metal poisoning and cardiovascular diseases. One of the primary applications of EDTA chelation therapy is the removal of heavy metals like lead, mercury, and cadmium from the body. Prolonged exposure to these metals can lead to various health issues, including neurologic and cardiovascular problems. Chelation therapy aims to mitigate these risks by aiding the elimination of these toxic substances. EDTA chelation has been investigated as a potential treatment for cardiovascular diseases, particularly atherosclerosis. The therapy is believed to work by removing calcium deposits from arterial walls, potentially improving blood flow and reducing the risk of heart-related complications. Some proponents argue that chelation therapy can lead to reduced symptoms and enhanced quality of life for individuals with cardiovascular issues. Chelation therapy has also been considered for individuals with peripheral artery disease (PAD), which causes reduced blood flow to the limbs. In medicine, EDTA chelation therapy has been utilized as an alternative treatment for heavy metal poisoning, particularly lead and mercury. Chelation therapy involves the administration of EDTA, which binds to toxic metal ions in the bloodstream, facilitating their excretion from the body. Beyond metal detoxification, some proponents claim that

chelation therapy could aid in managing certain cardiovascular conditions by reducing arterial plaque. EDTA's chelating properties extend to industrial processes as well. It serves as a key ingredient in various cleaning agents, detergents, and cosmetics due to its capacity to prevent unwanted metal-catalyzed reactions. Additionally, EDTA is employed in the food industry to preserve color, flavor, and nutrient content in certain products. Environmental applications of EDTA chelation involve soil remediation and water treatment. It helps extract heavy metal contaminants from soil, rendering them less harmful to plant and aquatic life. In water treatment, EDTA aids in sequestering metal ions, preventing their adverse effects in aquatic ecosystems. Some medical professionals argue that established treatments for cardiovascular diseases and heavy metal poisoning, such as medications and interventions, have a stronger scientific foundation. They emphasize the importance of evidence-based medicine and caution against relying solely on alternative therapies like chelation. Chelation therapy using EDTA has not been approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for certain applications, such as the treatment of cardiovascular diseases. This lack of approval underscores the need for more comprehensive research to validate its safety and efficacy [1-4].

CONCLUSION

EDTA chelation therapy remains a subject of considerable debate within the medical community and among individuals seeking alternative treatments. While the therapy's mechanism holds promise for heavy metal detoxification and potential cardiovascular benefits, its effectiveness and safety require further investigation. As with any medical intervention, individuals considering chelation therapy should consult their healthcare providers, weighing the potential benefits against the risks and exploring established treatments. The ongoing research in this field will provide a clearer understanding of EDTA chelation's role in maintaining health and managing certain medical conditions.

ACKNOWLEDGEMENT

None.

Received:	01-May-2023	Manuscript No:	ipjhmct-23-17453
Editor assigned:	03-May-2023	PreQC No:	ipjhmct-23-17453 (PQ)
Reviewed:	17-May-2023	QC No:	ipjhmct-23-17453
Revised:	22-May-2023	Manuscript No:	ipjhmct-23-17453 (R)
Published:	29-May-2023	DOI:	10.21767/2473-6457.23.3.21

Corresponding author Pascal Janet, Department of Pediatrics, Sullivan University, USA, E-mail:p_ja@gmail.com

Citation Janet P (2023) Exploring the Benefits and Controversies of EDTA Chelation Therapy. J Heavy Met Toxicity Dis. 08:21.

Copyright © 2023 Janet P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CONFLICT OF INTEREST

The author states there is no conflict of interest.

REFERENCES

1. Swart L, Reiniers C, Bagguley T (2018) Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. *Haematologica*. 103(1):69-79
2. Pascal L, Beyne-Rauzy O, Brechignac S (2013) Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndromic patients. *Br J Haematol*. 162(3):413-415
3. Leitch HA, Parmar A, Wells RA (2017) Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDSCAN analysis. *Br J Haematol*. 179(1):83-97
4. Angelucci E, Li J, Greenberg PL (2018) Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low-and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the randomized, double-blind Teleso study. *Blood*. 132:234